Rifampicin as cytotoxic agent for cholangiocarcinoma: preliminary report of seven cases.
Seven consecutive patients with unresectable cholangiocarcinoma of the major bile ducts, referred to one surgical department with a hepatobiliary interest, were treated by biliary decompression and with the antibiotic rifampicin in an uncontrolled preliminary study. Three patients were also given tamoxifen. Five of the seven are dead, the mean survival being 26 months (expected mean survival 8 months), and two are alive and well in May 1991, 48 and 30 months respectively from the time of presentation. A controlled study of rifampicin with and without tamoxifen is indicated in unresectable cholangiocarcinoma.
Sali
A
A
University of Melbourne, Department of Surgery, Victoria, Australia.
McQuillan
T
T
Read
A
A
Kune
G
G
D002759:Adenoma, Bile Duct / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001650:Bile Duct Neoplasms; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use
D013629:Tamoxifen; D012293:Rifampin